Karen Henson
Psychiatric/Mental Health · Frisco, TXNPI 1730723933
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 694 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,422, 3.9 times the $1,145 reported in 2022. Among psychiatric/mental health clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 694 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Neurocrine Biosciences, Inc.$974
- Otsuka America Pharmaceutical, Inc.$879
- plus $6K from 27 others
What the payments were for
- Food & beverage$13,102100%
- Education$490%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 92 | $1,904 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 55 | $1,249 |
| AbbVie | 79 | $1,216 |
| Teva Pharmaceuticals USA, Inc. | 51 | $1,003 |
| Neurocrine Biosciences, Inc. | 49 | $974 |
| Otsuka America Pharmaceutical, Inc. | 56 | $879 |
| Corium, LLC | 36 | $804 |
| Alkermes, Inc. | 34 | $754 |
| Axsome Therapeutics, Inc. | 24 | $558 |
| Lundbeck LLC | 31 | $544 |
| Ironshore Pharmaceuticals Inc. | 28 | $411 |
| E.r. Squibb & Sons, L.L.C. | 21 | $370 |
| Indivior Inc. | 17 | $352 |
| Supernus Pharmaceuticals, Inc. | 19 | $300 |
| Almatica Pharma LLC | 13 | $233 |
| Vanda Pharmaceuticals Inc. | 13 | $223 |
| Tris Pharma Inc | 12 | $198 |
| Noven Therapeutics, LLC | 9 | $169 |
| Neos Therapeutics, LP | 9 | $166 |
| Merck | 8 | $123 |
| Janssen Scientific Affairs, LLC | 3 | $115 |
| Idorsia Pharmaceuticals US Inc | 6 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $98 |
| Vertical Pharmaceuticals, LLC | 4 | $80 |
| Sage Therapeutics, LLC | 3 | $62 |
| Sunovion Pharmaceuticals Inc. | 4 | $50 |
| Avion Pharmaceuticals | 3 | $49 |
| Collegium Pharmaceutical, Inc. | 3 | $46 |
| Orexo US, Inc. | 2 | $25 |
| Braeburn Inc. | 1 | $25 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Eisai Inc. | 1 | $19 |
| OWP Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,151 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vilazodone Hcl | 11 | $1,941 |
| Oxcarbazepine | 26 | $1,397 |
| Aripiprazole | 27 | $1,227 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $989 |
| Hydroxyzine Hcl | 42 | $795 |
| Doxepin Hcl | 11 | $769 |
| Buspirone Hcl | 75 | $655 |
| Modafinil | 15 | $534 |
| Escitalopram Oxalate | 28 | $478 |
| Trazodone Hcl | 63 | $474 |
| Bupropion XlBupropion Hcl | 18 | $468 |
| Clonazepam | 88 | $457 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $442 |
| Sertraline Hcl | 44 | $415 |
| Fluoxetine Hcl | 33 | $397 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $233 | $41544 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.
Other psychiatric/mental health in Frisco
- Elias AlharariFrisco$41K
- Tracy HicksLongview$684K
- Natalie TellezHouston$602K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
- Monique GonzalezSan Antonio$126K
- Marguerite AddisonWaco$118K
- Komi Kokou-AbiRound Rock$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.